Michael K. Keng, MD

PRIMARY APPOINTMENT:

Associate Professor, Medicine: Hematology/Oncology

CONTACT:

UVA Division of Hematology/Oncology
PO Box 800716
Charlottesville, VA. 22908
Telephone: 434.924.4257
Fax: 434.244.7534
Email: mk2pv@virginia.edu

• Clinical Fellowship, Hematology/Oncology, Cleveland Clinic, Cleveland, Ohio
• MD, Michigan State University
• Residency, Internal Medicine, University of Southern California School of Medicine

Clinical trials in hematologic malignancies, including myelodysplastic syndromes and leukemias, with a special interest in treating the elderly population, determining optimal combinations and timing of targeted agents in MDS and leukemia, and studying patient safety and quality improvement.

• Pracinostat combined with azacitidine in newly diagnosed adult acute myeloid leukemia (AML) patients unfit for standard induction chemotherapy: PRIMULA phase III study.
  Garcia-Manero G, Kazmierczak M, Wierzbowska A, Fong CY, Keng MK, Ballinari G, Scarci F, Adès L.Leuk Res. 2024 May;140:107480. doi: 10.1016/j.leukres.2024.107480. Epub 2024 Mar 12.PMID: 38499457

• Phase I/II Study of DFP-10917 in Combination with Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia
  Study Contact: Cory Caldwell
• Phase II Trial of Cardioprotective Prophylaxis with Combination of Beta Blocker and Angiotensin-Converting Enzyme Inhibitors During Intensive Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia
  Study Contact: Cara Hanby
• A Phase I/II Dose Escalation and Expansion Study of BST-236 plus Venetoclax in Patients with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Induction Chemotherapy
  Study Contact: Cory Caldwell
• Phase I/II Study of DFP-10917 in Combination with Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia
  Study Contact: Cory Caldwell